Houman is a Managing Partner at SV Health Investors based out of their London offices. He has founded seven SV companies: Mestag Therapeutics, Sitryx Therapeutics, Enara Bio, Zarodex Therapeutics, TrexBio, Alchemab Therapeutics and Cellinta. Houman is also a member of the Investment Committee for the Dementia Discovery Fund and serves as a Director of Karus Therapeutics. Most recently, Houman was Vice President and Head of the Clinical Science group with UCB. Prior to joining UCB, he co-founded and served as a Director for both Cardiac Report and Heart Metabolics. He is Visiting Professor and Head of Experimental Therapeutics at the University of Oxford. Following his cardiology training, Houman was appointed as an honorary Consultant Cardiologist at the John Radcliffe Hospital in Oxford. Houman holds a BM BCh and a DPhil from the University of Oxford.